BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 2461688)

  • 1. Distinguishing features of idiopathic flushing and carcinoid syndrome.
    Aldrich LB; Moattari AR; Vinik AI
    Arch Intern Med; 1988 Dec; 148(12):2614-8. PubMed ID: 2461688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
    Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
    Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pronounced flush symptoms in carcinoid syndrome without liver metastases].
    Roth J; Raschka C; Hammar CH
    Leber Magen Darm; 1994 Nov; 24(6):259-61. PubMed ID: 7531269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
    Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
    N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathophysiological causes and clinical significance of flushing.
    Ray D; Williams G
    Br J Hosp Med; 1993 Nov 17-Dec 14; 50(10):594-8. PubMed ID: 8293240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome.
    Oberg K; Norheim I; Theodorsson E; Ahlman H; Lundqvist G; Wide L
    J Clin Endocrinol Metab; 1989 Apr; 68(4):796-800. PubMed ID: 2466045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carcinoid syndrome. Medical management.
    Clarke B; Hodgson HJ
    Br J Hosp Med; 1986 Mar; 35(3):146-8, 150, 152. PubMed ID: 3742126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A prolonged-action somatostatin analog and carcinoid syndrome].
    Chayvialle JA
    Bull Acad Natl Med; 1989 May; 173(5):643-50; discussion 650-1. PubMed ID: 2478266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flush symptoms caused by a mesenteric carcinoid without liver metastases.
    Sonnet S; Wiesner W
    JBR-BTR; 2002; 85(5):254-6. PubMed ID: 12463502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical assessment of niacin deficiency among carcinoid cancer patients.
    Shah GM; Shah RG; Veillette H; Kirkland JB; Pasieka JL; Warner RR
    Am J Gastroenterol; 2005 Oct; 100(10):2307-14. PubMed ID: 16181385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tachykinins in carcinoid tumors: their use as a tumor marker and possible role in the carcinoid flush.
    Norheim I; Theodorsson-Norheim E; Brodin E; Oberg K
    J Clin Endocrinol Metab; 1986 Sep; 63(3):605-12. PubMed ID: 2426299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.
    Ruszniewski P; Ish-Shalom S; Wymenga M; O'Toole D; Arnold R; Tomassetti P; Bax N; Caplin M; Eriksson B; Glaser B; Ducreux M; Lombard-Bohas C; de Herder WW; Delle Fave G; Reed N; Seitz JF; Van Cutsem E; Grossman A; Rougier P; Schmidt W; Wiedenmann B
    Neuroendocrinology; 2004; 80(4):244-51. PubMed ID: 15627802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flushing in the carcinoid syndrome and plasma kallikrein.
    Lucas KJ; Feldman JM
    Cancer; 1986 Nov; 58(10):2290-3. PubMed ID: 2428458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Octreotide treatment of carcinoid hypertensive crisis.
    Warner RR; Mani S; Profeta J; Grunstein E
    Mt Sinai J Med; 1994 Sep; 61(4):349-55. PubMed ID: 7969229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary carcinoid tumor of the bilateral testis associated with carcinoid syndrome.
    Son HY; Ra SW; Jeong JO; Koh EH; Lee HI; Koh JM; Kim WB; Park JY; Shong YK; Lee KU; Kim GS; Kim MS
    Int J Urol; 2004 Nov; 11(11):1041-3. PubMed ID: 15509216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The carcinoid syndrome.
    Maton PN
    JAMA; 1988 Sep; 260(11):1602-5. PubMed ID: 2457717
    [No Abstract]   [Full Text] [Related]  

  • 17. Serotonin, catecholamines, and spontaneous midgut carcinoid flush: plasma studies from flushing and nonflushing sites.
    Matuchansky C; Launay JM
    Gastroenterology; 1995 Mar; 108(3):743-51. PubMed ID: 7533112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A favorable response to the somatostatin analog SMS 201-995 in a patient with the carcinoid syndrome].
    Del Val A; Ponce J; Talens A; Martí-Bonmati L; Garrigues V; Berenguer J
    Rev Esp Enferm Dig; 1991 Mar; 79(3):215-7. PubMed ID: 2043408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ophthalmic manifestations of the carcinoid flush.
    Wong VG; Melmon KL
    N Engl J Med; 1967 Aug; 277(8):406-9. PubMed ID: 4378294
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of malignant carcinoid syndrome with a long-acting somatostatin analogue.
    Altman AR; Tschen JA; Rice L
    Arch Dermatol; 1989 Mar; 125(3):394-6. PubMed ID: 2923448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.